DGAP-News

Eckert & Ziegler to Start Development of Radioisotope Production Facility in Jintan, PR China

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous Eckert & Ziegler to Start Development of Radioisotope Production Facility in Jintan, PR China 12.02.2021 / 10:52 The issuer is solely responsible for the content of this announcement. Berlin, 12 February 2021. Eckert & Ziegler (ISIN DE0005659700), a global specialist for radioactive medical and industrial applications based in Berlin, Germany, has signed an investment agreement with the Administrative Committee of Jiangsu Jintan Economic Development Zone (PR China) for the acquisition and commercial development of 13.300 square meters of industrial-use land. Provided that Eckert & Ziegler successfully completes the public bidding process, the site will be wholly owned by a 100% subsidiary of Eckert & Ziegler. Subject to governmental and regulatory approval in China, it will house various radiopharmaceutical and radioisotope production suites and Eckert & Ziegler's administrative headquarter for the greater China area. At a later stage, it will also serve as the operational basis for maintenance crews and Eckert & Ziegler's different technical divisions. Radiopharmaceutical infrastructure for third party lease-in may be available, too.

Construction on the premises is anticipated to start this year. The completion of the building and the operational readiness of the various suites will happen in stages. Total investment volume until 2027, including land, buildings, technical equipment, and intangible assets may add up to 50 million Euros. If the process develops as envisaged, the facility is supposed to handle and manufacture a broad range of radioactive pharmaceutical and industrial products in its final stage. Eckert & Ziegler will be able to fund the development of the site through its regular cash-flow.

"The health system in China has made tremendous advances during the last decades", explains Andreas Eckert, Founder and CEO of Eckert & Ziegler. "Innovative therapies for the treatment of cancer are more and more available now also to Chinese patients. As strategic supplier to many international oncology companies, Eckert & Ziegler needs to be present in China with its own broadly licensed radiation facility and a strong local team. The investment agreement executed with Jintan will bring us closer to this important objective".

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at various locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [e-mail], www.ezag.com

---

12.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Eckert & Ziegler Strahlen- und Medizintechnik AG
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1167943

End of News	DGAP News Service

1167943  12.02.2021